Daclatasvir, cure that works across multiple hepatitis C genotypes, allows up to 90 percent of UK patients the choice of a potentially curative oral medication regimen that will not include interferon, a standard of care commonly connected with sustained flu-like side effects. In 2014, the New England Journal of Medication reported that daclatasvir , used in combination with sofosbuvir, offered scientific cure rates of 98 percent and 89 percent in sufferers with hepatitis C genotype 1 and 3 respectively. Daclatasvir has also shown, in another study, to supply clinical cure prices in hepatitis C genotype 4 as high as 100 percent when combined with peginterferon alfa and ribavirin what does tbol do .